Related Experiment Video

Updated: Jun 4, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants

C R Reis1, A M van der Sloot, A Natoni

  • 1Department of Pharmaceutical Biology, University of Groningen, The Netherlands.

Cell Death & Disease
|March 4, 2011
PubMed

Insights

Researchers engineered tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants that selectively target cancer cell death receptors (DR4 or DR5). These engineered TRAIL variants show enhanced cancer-killing activity, paving the way for more effective cancer treatments.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent that induces apoptosis via death receptors 4 (DR4) and 5 (DR5).
  • Cancer cells often rely on a single death receptor for TRAIL-induced apoptosis, suggesting that receptor-selective TRAIL agonists could be more potent.

Purpose of the Study:

  • To design and develop TRAIL variants with enhanced selectivity for DR4 or DR5.
  • To evaluate the efficacy of these selective TRAIL variants in inducing apoptosis in cancer cell lines.

Main Methods:

  • Computer-aided structure-based design was employed to create TRAIL variants.
  • Rational mutation strategies were used to achieve DR4 or DR5 selectivity.
  • Apoptosis-inducing activity was assessed in various cancer cell lines in vitro.

Main Results:

  • Engineered TRAIL variants demonstrated exclusive signaling via DR4 with enhanced affinity and potent apoptosis-inducing activity.
  • DR4-selective TRAIL variants were effective against both TRAIL-sensitive and -resistant cancer cell lines.
  • Combined treatment with DR4- and DR5-selective TRAIL variants significantly increased apoptosis compared to wild-type TRAIL.

Conclusions:

  • TRAIL-induced apoptosis via high-affinity, rapid, and selective homotrimerization of DR4 or DR5 represents a significant advancement in cancer therapy.
  • Development of receptor-selective TRAIL agonists offers a promising strategy for more efficient and targeted cancer treatment.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the 20th century...